FDA says Novartis withheld data problem before drug approval
U.S. regulators want to know why Novartis didn’t disclose a problem with testing data until after the Swiss drugmaker’s $2.1 million gene therapy was approved.
The Food and Drug Administration said Tuesday the manipulated data involved testing in animals, not patients, and it’s confident that the drug, called Zolgensma, should remain on the market.
The agency said it’s investigating and will consider criminal or civil penalties if appropriate.
Novartis falls after FDA says there were “data manipulation” issues in the application for its new gene therapy, but believes the drug should stay on the market. The FDA “will use its full authorities to take action, if appropriate, which may include civil or criminal penalties” pic.twitter.com/84PQHgjTgE
— CNBC Now (@CNBCnow) August 6, 2019
Zolgensma was approved in May for children under 2, becoming the most expensive treatment ever.
It’s a one-time treatment for a rare inherited condition, spinal muscular atrophy, which destroys a baby’s muscle control.
The FDA said in a statement that AveXis Inc., the Novartis AG subsidiary that manufactures Zolgensma, told the agency five weeks after the approval about a “data manipulation issue” that resulted in inaccurate information about testing in animals. The agency said the company knew about the problem before the FDA approved Zolgensma.
The inaccurate data is a small subset of the testing information that the FDA evaluated.
Acting FDA Commissioner Ned Sharpless tweeted that “the agency will use its full authorities to take action.”
In a statement Tuesday evening, Novartis said that after AveXis learned of alleged data manipulation in one animal testing procedure, the company immediately began investigating.
Once it had “interim conclusions,” it shared them with the FDA.
Novartis didn’t say why it didn’t notify the FDA before it approved Zolgensma.
It also stated that the animal test in question isn’t used in making the therapy for patients and that Zolgensma is safe and effective.
FDA staff inspected the company’s Irvine, California, manufacturing plant in recent weeks, then issued a report finding several deficiencies, including not fully following quality control procedures.
Spinal muscular atrophy strikes about 400 babies born in the U.S. each year and is a top genetic cause of infant death.
Zolgensma works by supplying a healthy copy of the faulty gene that causes the condition.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education.
The AP is solely responsible for all content.
The Western Journal has reviewed this Associated Press story and may have altered it prior to publication to ensure that it meets our editorial standards.
Truth and Accuracy
We are committed to truth and accuracy in all of our journalism. Read our editorial standards.
